Police describe what officers saw when they arrived at FedEx shooting scene in Indianapolis.
Police describe what officers saw when they arrived at FedEx shooting scene in Indianapolis.
New York, New York--(Newsfile Corp. - May 12, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Root, Inc (NASDAQ: ROOT) alleging that the Company violated federal securities laws.This lawsuit is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Root Class A common stock pursuant and/or traceable to the Offering Documents issued ...
The "FDA's Medical Device Software Regulation Strategy" conference has been added to ResearchAndMarkets.com's offering.
(FUBO) shares are trading sharply higher on Wednesday after the virtual cable service posted better-than-expected results for the March quarter. Fubo is a virtual MVPD, or multichannel video programming distributor, a jargony description for the business of providing a package of streaming cable services via set-top boxes like Roku, Apple TV and Amazon Fire TV. The company competes with services like YouTube TV, Sling and Hulu + Live TV.
It’s something that most of us wouldn’t even notice, but streaming video in standard definition, rather than hi-def or Ultra HD, could have a huge impact on the planet.
Wendy's light its up in the first quarter. Here's why.
Insurers have paid out more than 700 million pounds ($988.89 million) so far in business interruption payments following a court ruling earlier this year, Britain's markets watchdog said on Wednesday. Insurers have made interim payments of 268 million pounds and final settlements totaling 433 million pounds, the Financial Conduct Authority said. The watchdog brought the closely watched test case on behalf of policyholders last June, saying it could affect 370,000 policyholders and 60 insurers, and it is now checking that payouts are going ahead quickly.
After a year of DIY haircuts and hacks, it's time to go for the chop.
The "Paint Protection Films - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
A federal judge rejected a plea agreement on Wednesday that called for 15 to 21 years in prison for a man authorities described as the world’s largest purveyor of child pornography. Eric Eoin Marques is entitled to withdraw his guilty plea from last year if the judge departs from the sentencing range prosecutors and defense attorneys recommended. “It's too flawed, and I also don't agree with the outcome,” Chuang said.
Estonia, Tallinn--(Newsfile Corp. - May 12, 2021) - 2020 has been a challenging year for everyone. Writing Metier has announced new writing service categories and introduces travel and medical writing services worldwide. Now it is possible to hire travel and medical-related assignments and content tasks. To ensure getting excellent services, Writing Metier has hired experienced and strong writers specifically for the medical and travel industries. The team of experts on medical content ...
New York, New York--(Newsfile Corp. - May 12, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Skillz Inc. f/k/a Flying Eagle Acquisition Corp. ("Skillz Inc.") (NYSE: SKLZ) between December 16, 2020 and April 19, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Northern District ...
The "Investigation Report on China's Iodixanol Market 2021-2025" report has been added to ResearchAndMarkets.com's offering.
The "Global Acute Myeloid Leukemia Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com's offering.
Passport Technology Inc. ("Passport"), a leading, worldwide provider of payment technology to the gaming industry, surpassed all internal milestones and exceeded Pechanga Resort Casino's expectations after a multi-year product performance review of Passport's LiveCage™ platform.
Berkeley Research Group, LLC (BRG), a global consulting firm with more than 1,200 associates worldwide, today announced that its Healthcare Performance Improvement (HPI) practice is collaborating with healthcare solutions provider Mednition to utilize KATE, Mednition's artificial intelligence(AI)–powered real-time triage decision-support solution designed specifically for emergency department (ED) nurses.
Fred Hutchinson Cancer Research Center to present updated interim data from ongoing MB-106 Phase 1/2 clinical trialWORCESTER, Mass., May 12, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that interim data from the ongoing Phase 1/2 clinical trial investigating the safety and efficacy of MB-106 CD20-targeted CAR T for high-risk B-cell non-Hodgkin lymphomas (“B-NHL”) and chronic lymphocytic leukemia (“CLL”) has been selected for an e-poster presentation at the European Hematology Association 2021 Virtual Congress (“EHA2021”). MB-106 is being developed in a collaboration between Mustang and Fred Hutchinson Cancer Research Center (“Fred Hutch”). In the abstract posted today on the EHA2021 website, Fred Hutch reported on 12 patients treated with MB-106, which underwent a major cell manufacturing modification after treating the first 7 patients as previously reported at the 62nd Annual American Society of Hematology meeting in 2020. The 12 patients treated under the new manufacturing process were treated at dose levels (“DL”) ranging from 3.3x105 to 1x107 CAR T cells/kg, and clinical responses were observed at all DLs with no dose-limiting toxicities. Cytokine release syndrome occurred in 3 patients (25%): 2 patients with grade 1 and 1 patient with grade 2. Only 1 patient required tocilizumab and dexamethasone, and no immune effector cell-associated neurotoxicity syndrome of any grade was observed. Overall response rate (“ORR”) was 92% (11/12) with a complete response (“CR”) rate of 58% (7/12). In 9 patients with follicular lymphoma, ORR and CR were 89% (8/9) and 67% (6/9), respectively. The patient with CLL had a PET-negative CR and undetectable measurable residual disease in peripheral blood and bone marrow by flow cytometry (10-4) (uMRD4) on day 28. Among patients who received the highest two dose levels, DL3 (3.3x106 CAR T cells/kg; n=4) and DL4 (1x107 CAR T cells/kg; n=1), CR rate was 100% (5/5). All 7 patients who achieved a CR remain in remission at a median follow-up of 4 months. CAR T expansion was robust, with median peak blood levels of CAR+ T cells of 122 CAR+ cells/μl (range 0.27-2024), corresponding to 19% (range 0.15 - 65%) of all CD3+ cells. Updated data will be presented at EHA2021. Manuel Litchman, M.D., President and Chief Executive Officer of Mustang, said, “We are pleased that Fred Hutch will present interim data from the ongoing Phase 1/2 trial of MB-106 at EHA2021. The data thus far indicate that MB-106 has a highly favorable safety profile at all dose levels when compared to commercially available CAR T cell therapies targeting CD19. We look forward to the continued progression of this CD20-targeted CAR T cell therapy program for patients with relapsed or refractory B-cell non-Hodgkin lymphomas and CLL.” Details of the MB-106 e-poster presentation are as follows: Topic: 25. Gene therapy, cellular immunotherapy and vaccination – Clinical Abstract Code: EP731Title: Immunotherapy Using a 3rd Generation CD20 Targeted CAR T-Cell (MB-106) for Treatment of B-Cell Non-Hodgkin Lymphoma (B-NHL) and Chronic Lymphocytic Leukemia (CLL) Presenter: Mazyar Shadman, M.D., M.P.H., Fred Hutchinson Cancer Research Center, Seattle, WA, USADate and Time: All e-posters will be available for viewing on June 11, 2021 at 09:00 Central European Summer Time (CEST) / 3 a.m. ET A copy of the abstract can be viewed online through the EHA2021 website at https://ehaweb.org. About Mustang BioMustang Bio, Inc. (“Mustang”) is a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases. Mustang aims to acquire rights to these technologies by licensing or otherwise acquiring an ownership interest, to fund research and development, and to outlicense or bring the technologies to market. Mustang has partnered with top medical institutions to advance the development of CAR T therapies across multiple cancers, as well as a lentiviral gene therapy for XSCID. Mustang is registered under the Securities Exchange Act of 1934, as amended, and files periodic reports with the U.S. Securities and Exchange Commission (“SEC”). Mustang was founded by Fortress Biotech, Inc. (NASDAQ: FBIO). For more information, visit www.mustangbio.com. Forward‐Looking StatementsThis press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock value. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to our growth strategy; our ability to obtain, perform under, and maintain financing and strategic agreements and relationships; risks relating to the results of research and development activities; risks relating to the timing of starting and completing clinical trials; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law, and we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Company Contacts:Jaclyn Jaffe and Bill BegienMustang Bio, Inc.(781) email@example.com Investor Relations Contact:Daniel FerryLifeSci Advisors, LLC(617) firstname.lastname@example.org Media Relations Contact:Tony Plohoros6 Degrees(908) email@example.com
As reports trickle in, here's what we know so far about what the Patriots' 2021 schedule looks like.
"I'll say that I'm Black and I'm proud," said Viola Fletcher, who was 7 years old when as many as 300 people died in Tulsa
Whether you have FODO or JODO (that's joy of dining out), these tips will help you stay safe.
Tanitoluwa "Tani" Adewumi, who once lived in a New York City homeless shelter, has achieved a remarkable title for someone his age: chess master.